TLX101 for Glioblastoma Therapy - Clinical Trial Update
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallMelbourne (Australia) – 17 June 2021. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that patient recruitment into the IPAX-1 Ph I/II study of TLX101 (4-L- 131 [ I] iodo-phenylalanine) in combination with external beam radiation therapy in recurrent glioblastoma multiforme (GBM), will be closed. Interim analysis of safety and preliminary efficacy is sufficiently encou
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Update on FDA New Drug Application Review for Illuccix
- US Co-Promotion with EZAG for Prostate Cancer Imaging
- TLX66 Meets Study Objectives in Patients with AL Amyloidosis
- German Distribution Agreement with Eckert and Ziegler
- Phase III Prostate Cancer Therapy Clinical Trial Commences
Later from Telix Pharmaceuticals
- ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update
- App 4C and Activities Report for June 2021 Quarter
- Telix Seneffe Production Facility - Progress Update
- TLX66 in Phase II Academic Study of Pediatric Leukemia
- Telix and Merck pan-cancer clinical collaboration
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals